Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Phase 2 Terminated 10 enrolled Sandy Srinivas Genentech, Inc. · collab Novartis · collab

NaSingle-groupOpen-labelTreatment

To determine the safety and efficacy of the combination of bevacizumab and everolimus (RAD001) for the treatment of metastatic renal cell cancer

Outcome not reported

Stopped (Enrollment): “slow accrual”

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Everolimus	Small molecule	10 mg	Oral